Novo Nordisk

What we do

Driving long-term health by discovering, developing and delivering

We refuse to accept the status quo for people living with serious chronic diseases. For more than century, we have translated unmet medical needs into innovative medicines and delivery systems, like our insulin pens, and today we continue to reimagine what’s possible through bold science.

From our labs to our factory floors, we are discovering and developing innovative biological medicines and making them accessible to people living with diabetes, obesity, and rare blood and endocrine diseases around the world.

Once a breakthrough treatment is created in our labs, we want it to reach as many people as possible. To keep up with demand, we scale fast. We build big. We optimise at every opportunity. By building capacity to a level previously unheard of in our industry, we can make a difference in more lives than ever before.

Our pioneering approach in medicine… and beyond

Defeating serious chronic diseases requires innovative and convenient treatments – but success in creating long-term health also depends on seeking out new ways to advance prevention and expand access to care.

Our global presence

50%

of the world's insulin is Novo Nordisk produced.

45m+

people living with diabetes and obesity reached last year.

800m+

number of insulin pens we produced last year.

40+

countries where we conduct clinical trials.

NOVO NORDISK HQ

Novo Nordisk A/S
Novo Alle 1
2880 Bagsværd
Denmark
+45-4444-8888
CVR-no. 24256790

‍